A multi-center, obsevational safety registry of subjects with idiopathic Parkinson's disease previously treated with intraputaminal infusion of liatermin.
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2010
At a glance
- Drugs Liatermin (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Amgen
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Feb 2010 Actual end date (Sep 2007) added as reported by ClinicalTrials.gov.
- 28 Mar 2006 New trial record.